Open AccessCD 155, an onco‐immunologic molecule in human tumors
Author(s) -
Gao Jian,
Zheng Qianqian,
Xin Na,
Wang Wei,
Zhao Chenghai
Publication year - 2017
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13324
Subject(s) - tigit , biology , immune system , receptor , cancer research , antibody , immunology , nectin , cell adhesion molecule , natural killer cell , t cell , cell , cell adhesion , cytotoxic t cell , in vitro , genetics
CD 155 is the fifth member in the nectin‐like molecule family, and functions as the receptor of poliovirus; therefore, CD 155 is also referred to as necl‐5, or PVR . As an immunoglobulin‐like adhesion molecule, CD 155 is involved in cell motility, and natural killer and T cell‐mediated immunity. CD 155 is barely or weakly expressed in various normal human tissues, but frequently overexpressed in human malignant tumors. CD 155 overexpression promotes tumor cell invasion and migration, and is associated with tumor progression and poor prognosis. As the ligand for both costimulatory receptor CD 226 and coinhibitory receptor TIGIT and CD 96 on natural killer and T cells, CD 155 seems to play a dual role in oncoimmunity. However, some recent studies indicate that CD 155 overexpression may induce tumor immune escape. Taken together, CD 155 may be considered as a target for the treatment of tumors with CD 155 overexpression.